Similar articles for PMID: 25222473

Year	Number of Results
2007	1
2008	2
2009	7
2010	8
2011	14
2012	11
2013	25
2014	20
2015	9
2016	5
2017	1
2018	2
2019	1
2020	1
2022	1
2023	1
2024	0

1

Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations.

Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou X, Frankel W, Otterson GA, Beall HD, Zhao W. Yilmaz A, et al. Int J Environ Res Public Health. 2014 Sep 12;11(9):9491-502. doi: 10.3390/ijerph110909491. Int J Environ Res Public Health. 2014. PMID: 25222473 Free PMC article.

2

Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.

Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou XP, Frankel W, Otterson GA, Zhao W. Yilmaz A, et al. Int J Environ Res Public Health. 2014 Aug 25;11(9):8645-60. doi: 10.3390/ijerph110908645. Int J Environ Res Public Health. 2014. PMID: 25158139 Free PMC article.

3

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P. Lim EH, et al. J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28. J Thorac Oncol. 2009. PMID: 19096301 Free article.

4

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L. Ludovini V, et al. J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b. J Thorac Oncol. 2011. PMID: 21258250 Free article.

5

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.

Ragusa M, Vannucci J, Ludovini V, Bianconi F, Treggiari S, Tofanetti FR, Flacco A, Colella R, Sidoni A, Crinò L, Puma F. Ragusa M, et al. Am J Clin Oncol. 2014 Aug;37(4):343-9. doi: 10.1097/COC.0b013e31827a7e7a. Am J Clin Oncol. 2014. PMID: 23357969

6

Molecular alterations in non-small cell lung carcinomas of the young.

VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z. VandenBussche CJ, et al. Hum Pathol. 2014 Dec;45(12):2379-87. doi: 10.1016/j.humpath.2014.08.005. Epub 2014 Sep 2. Hum Pathol. 2014. PMID: 25288236

7

Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)?

Kim ST, Sung JS, Jo UH, Park KH, Shin SW, Kim YH. Kim ST, et al. Med Oncol. 2013 Mar;30(1):328. doi: 10.1007/s12032-012-0328-3. Epub 2013 Jan 10. Med Oncol. 2013. PMID: 23307237

8

Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.

Jiang L, Huang J, Morehouse C, Zhu W, Korolevich S, Sui D, Ge X, Lehmann K, Liu Z, Kiefer C, Czapiga M, Su X, Brohawn P, Gu Y, Higgs BW, Yao Y. Jiang L, et al. Cancer Genet. 2013 Sep-Oct;206(9-10):330-9. doi: 10.1016/j.cancergen.2013.09.004. Epub 2013 Oct 2. Cancer Genet. 2013. PMID: 24200637 Free article.

9

KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.

Maus MK, Grimminger PP, Mack PC, Astrow SH, Stephens C, Zeger G, Hsiang J, Brabender J, Friedrich M, Alakus H, Hölscher AH, Lara P, Danenberg KD, Lenz HJ, Gandara DR. Maus MK, et al. Lung Cancer. 2014 Feb;83(2):163-7. doi: 10.1016/j.lungcan.2013.11.010. Epub 2013 Nov 21. Lung Cancer. 2014. PMID: 24331409

10

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC. Kim HR, et al. Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30. Cancer. 2012. PMID: 21720997 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

93 results

Results by year